Abstract
In this paper the authors investigated a synergistic antimycotic effect between four antifungal drugs Amphotericin B, Fluconazole, Tioconazole, and Flucytosine individually combined with Anidulafungin compound. This latter is considered a drug of choice in the treatment of fungal infections; it has good activity both in vitro and in vivo against yeasts and moulds, as Candida and Aspergillus. The goal of this study was to evaluate the in vitro interaction of Anidulafungin in the synergic combinations with previous reported drugs against 12 Candida strains according to CLSI M27-A3 protocol. A synergistic interaction was observed against the most antifungal strains; in particular an increasing of the antimycotic efficacy was obtained from the association between Anidulafungin and Amphotericin B or Fluconazole (Mixture 4:6). In contrast the association Tioconazole/Anidulafungin was less effective on fungal species growth. The antimycotics MIC reduction values were more evident against some strains as C. glabrata, C. krusei, C. tropicalis and C. parapsilosis.
Keywords: Amphotericin B, Anidulafungin, antifungal drugs, C. albicans, non- C. albicans, synergism, synergistic antimycotic, C. tropicalis, Candida and Aspergillus, C. parapsilosis
Medicinal Chemistry
Title:In vitro Synergy Testing of Anidulafungin with Fluconazole, Tioconazole, 5-Flucytosine and Amphotericin B against some Candida spp.
Volume: 8 Issue: 4
Author(s): Antonio Rosato, Monica Piarulli, Brigida Immacolata Pia Schiavone, Maria Teresa Montagna, Giuseppina Caggiano, Marilena Muraglia, Addolorata Carone, Carlo Franchini and Filomena Corbo
Affiliation:
Keywords: Amphotericin B, Anidulafungin, antifungal drugs, C. albicans, non- C. albicans, synergism, synergistic antimycotic, C. tropicalis, Candida and Aspergillus, C. parapsilosis
Abstract: In this paper the authors investigated a synergistic antimycotic effect between four antifungal drugs Amphotericin B, Fluconazole, Tioconazole, and Flucytosine individually combined with Anidulafungin compound. This latter is considered a drug of choice in the treatment of fungal infections; it has good activity both in vitro and in vivo against yeasts and moulds, as Candida and Aspergillus. The goal of this study was to evaluate the in vitro interaction of Anidulafungin in the synergic combinations with previous reported drugs against 12 Candida strains according to CLSI M27-A3 protocol. A synergistic interaction was observed against the most antifungal strains; in particular an increasing of the antimycotic efficacy was obtained from the association between Anidulafungin and Amphotericin B or Fluconazole (Mixture 4:6). In contrast the association Tioconazole/Anidulafungin was less effective on fungal species growth. The antimycotics MIC reduction values were more evident against some strains as C. glabrata, C. krusei, C. tropicalis and C. parapsilosis.
Export Options
About this article
Cite this article as:
Rosato Antonio, Piarulli Monica, Immacolata Pia Schiavone Brigida, Teresa Montagna Maria, Caggiano Giuseppina, Muraglia Marilena, Carone Addolorata, Franchini Carlo and Corbo Filomena, In vitro Synergy Testing of Anidulafungin with Fluconazole, Tioconazole, 5-Flucytosine and Amphotericin B against some Candida spp., Medicinal Chemistry 2012; 8 (4) . https://dx.doi.org/10.2174/157340612801216184
DOI https://dx.doi.org/10.2174/157340612801216184 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clozapine and COVID-19: A Case Report and Clinical Considerations
Current Drug Safety Hypovitaminosis D in Healthy Pregnant Women and their Newborns in Greece
Endocrine, Metabolic & Immune Disorders - Drug Targets Carnosine and Kidney Diseases: What We Currently Know?
Current Medicinal Chemistry Editorial
Current Diabetes Reviews Pharmacogenomics and Personalized Use of Drugs
Current Topics in Medicinal Chemistry Conantokins: Peptide Antagonists of NMDA Receptors
Current Medicinal Chemistry A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type
Current Alzheimer Research Type I Glycogen Storage Diseases: Disorders of the Glucose-6- Phosphatase Complex
Current Molecular Medicine Stimuli-induced Pulsatile or Triggered Release Delivery Systems for Bioactive Compounds
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Hepatocarcinogenesis and Ceramide/Cholesterol Metabolism
Anti-Cancer Agents in Medicinal Chemistry The Computational Analysis of Single Nucleotide Associated with MicroRNA Affecting Hepatitis B Infection
MicroRNA Metabolic Targeting of Malignant Tumors: Small-Molecule Inhibitors of Bioenergetic Flux
Recent Patents on Anti-Cancer Drug Discovery Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Enteral and Parenteral Nutrition Therapy for Crohns Disease
Current Pharmaceutical Design Pharmacological Properties of Thalidomide and its Analogues
Recent Patents on Inflammation & Allergy Drug Discovery Adult Stem Cells and Mammalian Epimorphic Regeneration-Insights from Studying Annual Renewal of Deer Antlers
Current Stem Cell Research & Therapy Stem Cells for the Treatment of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Advanced Glycation: Implications in Tissue Damage and Disease
Protein & Peptide Letters Endoplasmic Reticulum Stress Signaling Pathways: Activation and Diseases
Current Protein & Peptide Science Chemistry and Biology of Iminosugar Di- and Oligosaccharides
Current Chemical Biology